Non-Proliferative Diabetic Retinopathy Market Dynamics, Trends, Drivers, Growth Rate Size, Share Overview 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Non-Proliferative Diabetic Retinopathy Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $3.58 billion In 2028 At A CAGR Of 8.1% :

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp

Non-Proliferative Diabetic Retinopathy Market Major Segments
The non-proliferative diabetic retinopathy market covered in this report is segmented -

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

Key Driver - Residential Energy Management Market Surges With The Surge In Residential Building Construction

The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose (blood sugar) due to inadequate production of insulin by the pancreas or the body's cells becoming resistant to the effects of insulin. Diabetes is caused due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, resulting in vision impairment and potential blindness. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of diabetes associations, approximately 537 million adults (20-79 years old) were living with diabetes in 2021. In contrast, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15620&type=smp

Prominent Trend - Advancements In AI-Enabled Fundus Cameras For Non-Proliferative Diabetic Retinopathy

Major companies operating in the non-proliferative diabetic retinopathy market are developing AI-enabled cameras to improve patient outcomes and advance the field of ophthalmic imaging. AI-enabled cameras in ophthalmic imaging refer to devices equipped with artificial intelligence (AI) algorithms that assist in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, launched Optomed Aurora AEYE, a handheld AI fundus camera designed to detect more than mild diabetic retinopathy instantly. This innovative device combines the portability of a handheld camera with the power of artificial intelligence to provide high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images. This enables quick and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

Non-Proliferative Diabetic Retinopathy Market Players
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc. , Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Non-Proliferative Diabetic Retinopathy Market Report Structure
3. Non-Proliferative Diabetic Retinopathy Market Trends And Strategies
4. Non-Proliferative Diabetic Retinopathy Market - Macro Economic Scenario
5. Non-Proliferative Diabetic Retinopathy Market Size And Growth
…..
27. Non-Proliferative Diabetic Retinopathy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.